Drug Target Review

DECEMBER 20, 2024

These twins simulate how a patients condition might evolve without treatment, enabling researchers to compare the real-world effects of an experimental therapy against predicted outcomes. Regulators care a lot about controlling the Type 1 error rate of the clinical trial, Smith notes. Aaron received his Ph.D.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Chemical Biology and Drug Design

SEPTEMBER 24, 2023

This research is powered to probe whether the molecular mechanism of JAS for IS treatment is coupled with microglia polarization. JAS reduces IS injury by regulating microglia polarization via PASK-EEF1A1 axis. Abstract Jasminoidin (JAS) can alleviate ischemic stroke (IS) injury, but its molecular mechanism remains undefined.

Regulations 100

Regulations Protein Expression Treatment Research 100

Chemical Biology and Drug Design

JANUARY 7, 2024

The tumour killing effects of chrysophanol possible owing to its targeted regulation on mTOR. Screening by GEO software indicated that the mTOR signalling pathway is possibly regulated by chrysophanol. The beneficial effects of chrysophanol may be attribute to the targeted regulation of mTOR.

Regulations 100

Regulations Treatment Research 100

Agency IQ

APRIL 12, 2024

BY LAURA DIANGELO, MPH In the past few years, regulators and researchers have shown increased interest in leveraging decentralized trial methods – especially following the pandemic. In this article, AgencyIQ explores the current regulatory state of decentralized trials and what’s likely coming next.

Regulations 59

Regulations Trials Clinical Trials Research 59

Drug Patent Watch

FEBRUARY 27, 2025

Imagine investing years of research and development into a groundbreaking new medication, only to see it copied and sold in foreign markets without your permission. One key strategy is to conduct thorough market research and stay up-to-date on the latest patent laws and regulations in each country where you plan to operate.

Marketing 52

Marketing Drugs Regulations Pharmaceutical Companies 52

Drug Patent Watch

FEBRUARY 26, 2025

In this article, we'll delve into the world of drafting drug patent applications for biologic drugs. However, the patentability of biologics is governed by specific laws and regulations, such as the Biologics Price Competition and Innovation Act (BPCIA). Read the full article here: [link]

Drugs 59

Drugs Government Regulations Compliance 59

Chemical Biology and Drug Design

JANUARY 4, 2024

Furthermore, AS-IV performed a beneficial anti-cancer effect by regulating the circ_0001615/miR-873-5p/LASP1 network in the CRC. According to the IC50 of AS-IV in CRC cells, the 100 ng/mL AS-IV treatment for 24 h was chosen for the following research: Our data confirmed that AS-IV is a beneficial anti-cancer agent in CRC cells.

Regulations 100

Regulations RNA Treatment Research 100

Chemical Biology and Drug Design

FEBRUARY 19, 2024

However, the underlying molecular mechanism by which Icariin regulates osteogenic differentiation needs to be further revealed. The regulation of USP47 on SIRT1 was confirmed by ubiquitination detection and co-immunoprecipitation analysis. The viability of BMSCs was assessed by cell counting kit 8 assay.

Regulations 100

Regulations Protein Expression Research 100

PPD

MARCH 11, 2025

While individual rare diseases affect populations that are small in numbers, collectively they impact millions globally, posing significant health and research challenges. This solution allows researchers to enhance the robustness of their control populations, minimize bias and provide a real-world context to trial outcomes.

Drug Development 52

Drug Development Clinical Trials Disease Trials 52

Chemical Biology and Drug Design

JUNE 21, 2023

Hsa-miR-503-5p negatively regulates CTDSPL, suggesting its potential as a target to overcome cisplatin resistance in LUAD. Hsa-miR-503-5p bound to CTDSPL gene and promoted cisplatin resistance and malignant progression of LUAD cells by negatively regulating CTDSPL.

Regulations 100

Regulations Protein Expression Bioinformatics Drugs 100

Chemical Biology and Drug Design

FEBRUARY 3, 2025

ABSTRACT PTP-PEST (also known as PTPN12) regulates cellular signaling and transduction pathways by dephosphorylating its substrate. The invitro biochemical assays validated that J1-65 inhibits PTP-PEST activity competitively and the inhibitor binding stabilizes the protein-ligand complex.

Small Molecule 100

Small Molecule Biochemical Assays Regulations Drugs 100

Chemical Biology and Drug Design

JANUARY 24, 2024

From result of network analysis, the possible underlying mechanism of YH complex was closely related with the “regulation of hair cycle” and “apoptosis signaling pathway.” In summary, YH complex regulated hair development cycle by inhibiting the androgenic-apoptotic axis in AGA.

Regulations 100

Regulations Treatment Research 100

Chemical Biology and Drug Design

JANUARY 23, 2024

Matrine inhibits the growth and metastasis of hepatocellular carcinoma by regulating the ELAVL1/RBM3-mediated Wnt/β-catenin signaling pathway. Moreover, ELAVL1 might bind with RBM3 to positively regulate the stability of RBM3 mRNA. Nevertheless, the anti-tumor molecular mechanism of Martine in HCC is still not fully revealed.

Regulations 100

Regulations RNA Treatment Research 100

Chemical Biology and Drug Design

DECEMBER 13, 2024

Tectorigenin could reduce the expression levels of inflammatory cytokines in both DBV-infected THP-1 cells and plasma samples of IFNAR / mice infected with DBV. ABSTRACT Severe fever with thrombocytopenia syndrome (SFTS) is a severe emerging infectious disease caused by Dabie bandavirus (DBV).

Regulations 100

Regulations Disease Research 100

Chemical Biology and Drug Design

SEPTEMBER 6, 2023

Matrine inhibits TNBC cell proliferation, migration and invasion, promotes apoptosis, and suppresses tumor growth through down-regulation of HN1 expression. This study aimed to investigate the anti-tumor effect of matrine on the proliferation and apoptosis of TNBC cells based on HN1 regulation in vitro and in vivo.

Protein Expression 100

Protein Expression Regulations Treatment Drugs 100

Chemical Biology and Drug Design

MARCH 8, 2024

Circ_0139658 is directly bound to miR-653-5p to regulate YY1 expression. Brucine suppressed the proliferation, migration, and invasion of RA-FLSs, and alleviated inflammation by reducing the release of pro-inflammatory factors and macrophage M1 polarization. RA-FLSs showed increased circ_0139658 and YY1 levels and decreased miR-653-5p levels.

Regulations 100

Regulations RNA Treatment Research 100

Chemical Biology and Drug Design

JANUARY 24, 2024

Baicalin alleviates OGD/R-induced SK-N-SH cell apoptosis, inflammation, and ferroptosis in vitro, and brain injury in MCAO mice in vivo, via the regulation of miR-556-3p/ACSL4 pathway. In conclusion, BCL alleviated OGD/R-induced SK-N-SH cell injury and relieved brain injury in MCAO mice by regulating miR-556-3p/ACSL4 axis.

Regulations 100

Regulations RNA Treatment Research 100

Agency IQ

AUGUST 18, 2023

The new guidance offers recommendations for institutional review boards (IRBs), investigators and sponsors on key aspects of informed consent, significantly expanding FDA’s recommendations on several key topics, including reimbursement for research participation. The FDA, HHS, and research and informed consent policies In the U.S.,

FDA 52

FDA Clinical Trials Clinical Research Regulations 52

KIF1A

OCTOBER 7, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. In this week’s article, a multinational team of scientists investigated the genetics of patients with HSAN or a similar disorder, congenital insensitivity to pain.

Disease 111

Disease Treatment Regulations Therapies 111

Chemical Biology and Drug Design

MARCH 14, 2023

EVO regulates ovarian cancer progression through the NEAT1-miR-152-3p-CDK19 axis, which further advances the possibility of EVO as a therapeutic drug for ovarian cancer. EVO dose-dependently attenuated cell viability, induced G2/M phase arrest, and apoptosis in ovarian cancer cells.

Regulations 100

Regulations Bioinformatics Drugs Research 100

Chemical Biology and Drug Design

MARCH 8, 2024

Besides, SSD (4 μM) treatment could significantly up-regulate the cell viability and marker expression of PP-induced astrocytes. PP treatment (1 mM) induced cell injury by significantly reducing the viability of astrocytes and expression of cellular markers. SSD treatment (4 μM) had no toxicity to astrocytes.

Regulations 100

Regulations Treatment Research 100

KIF1A

OCTOBER 21, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. But what regulates the delivery of materials at these early stages?

Regulations 105

Regulations Doctors Disease Packaging 105

KIF1A

SEPTEMBER 16, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. In this week’s pre-print*, researchers at the Tata Institute of Fundamental Research in Mumbai investigated how a modification to UNC-104, the C.

Regulations 105

Regulations RNA Disease Research 105

Drug Target Review

APRIL 7, 2025

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Chemical Biology and Drug Design

JANUARY 4, 2024

Curcumin activates ATF6-regulated endoplasmic reticulum (ER) stress, promotes ATF6 nuclear translocation, activates Chop/Bax/Bcl-2/Caspase-3 apoptosis pathway, and promotes apoptosis of CRC cells. Abstract Colorectal cancer (CRC) is the main cause of cancer-associated death.

Regulations 189

Regulations Treatment Research 189

Agency IQ

NOVEMBER 27, 2023

The European Chemicals Agency is attempting to guide scientific research toward topics with regulatory relevance. Fill out the form to read the full article.

Research 59

Research Regulations 59

Alta Sciences

FEBRUARY 19, 2025

Beyond bioanalysis, understanding the mechanism of action is equally important, as different classes of oligonucleotidessuch as antisense oligonucleotides (ASOs)interact with mRNA in distinct ways to regulate gene expression. Our experts stay up to date on all new and evolving regulations to guarantee regulatory compliance in your studies.

Drug Development 52

Drug Development Clinical Pharmacology Immune Response Drugs 52

Chemical Biology and Drug Design

FEBRUARY 22, 2024

However, the role and mechanism of TMEM97 in regulating 5-FU resistance in CRC cells remains unclear. In conclusion, TMEM97 knockdown inhibited 5-FU resistance in CRC by regulating EMT and ABC transporter expression via inactivating the Akt/mTOR pathway. Transmembrane protein 97 (TMEM97) functions as an oncogene in CRC.

Regulations 100

Regulations Research 100

Chemical Biology and Drug Design

APRIL 1, 2023

Berberine has been shown in in vitro and in vivo studies to inhibit various types of cancer by activating the p-53 and cyclin-B expression, targeting various cell signalling pathways, to regulate the cell cycle. Many kinds of research are being focused on the cytotoxic activity of berberine in in vitro and in vivo studies.

Therapies 100

Therapies RNA Regulations Research 100

KIF1A

SEPTEMBER 23, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. While we usually think of this cause as KIF1A mutations, upstream regulators of motor proteins can also disrupt traffic. How does LRRK2 regulate axonal traffic?

Regulations 111

Regulations Disease Science Production 111

Agency IQ

MAY 31, 2024

What we expect EU chemical regulators to do in June 2024 Welcome to AgencyIQ’s monthly roundup of EU chemical sector activities. Another consultation is closing this month on a draft implementing regulation that is amending the label format for fluorinated greenhouse gases (F-gases) under the new F-gas Regulation (EU) 2024/573.

Regulations 40

Regulations Production International Government 40

Chemical Biology and Drug Design

JANUARY 5, 2024

Moreover, matrine also could regulate PDK1 expression to suppress AML progression. Mechanistically, miR-495-3p/miR-543 directly targeted PDK1, and the inhibition impacts of miR-495-3p/miR-543 on AML progression could be rescued by PDK1 overexpression.

Regulations 100

Regulations Production Research 100

Agency IQ

MARCH 1, 2024

What we expect EU regulators to do in March 2024 Welcome to AgencyIQ’s monthly roundup of EU chemical sector activities. ECHA consultations under the CLP Regulation closing in March CLP: Harmonized classification and labeling (CLH) Consultations on classification and labeling harmonization (CLH) are open for 60 days.

Regulations 40

Regulations Production Packaging Science 40

KIF1A

JANUARY 13, 2024

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. This study indicates that KIF1A and KIF13B have different impacts on these angles, regulating the number of RGPs and neurons in the developing brain.

DNA 105

DNA Regulations Drug Development Disease 105

KIF1A

MAY 4, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. In this week’s article, researchers in Brazil identified a KIF1A mutation in a cohort of patients with congenital ataxia.

Science 116

Science Medical Schools Research RNA 116

Agency IQ

JULY 8, 2024

What we expect European regulators to do in July 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

Regulations 40

Regulations Pharmaceuticals Production Vaccine 40

Agency IQ

MAY 3, 2024

What we expect European regulators to do in May 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40